We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Electronic Nose Technology May Facilitate Accurate Diagnosis of Sarcoidosis

By LabMedica International staff writers
Posted on 12 Apr 2022
Print article
Image: The SpiroNose (generic name: “eNose”) linked to the online BreathBase platform analyzes the mixture of volatile organic compounds (VOCs) in exhaled breath in real-time based on advanced signal processing and an extensive online reference database, infused with AI (Photo courtesy of Breathomix)
Image: The SpiroNose (generic name: “eNose”) linked to the online BreathBase platform analyzes the mixture of volatile organic compounds (VOCs) in exhaled breath in real-time based on advanced signal processing and an extensive online reference database, infused with AI (Photo courtesy of Breathomix)

Sarcoidosis is a granulomatous inflammatory disease without a known cause that can affect roughly any organ. The lungs are involved in the vast majority of patients (89% to 99%). Diagnosis can be challenging because no standardized diagnostic procedure exists. The three major criteria for diagnosis are compatible clinical features, pathology tissue assessment, and exclusion of other granulomatous diagnoses.

Breath biomarkers are increasingly studied in respiratory diseases, as exhaled volatile organic compounds (VOCs) reflect pathophysiological processes in the human body. Techniques such as gas chromatography and mass spectrometry can be used to identify individual VOCs, but are time-consuming and complex. Analysis of a profile of VOCs (a “breathprint”) using electronic nose (eNose) technology will be of added value in clinical practice.

Respiratory Medicine Specialists at the Erasmus Medical Center (Rotterdam, The Netherlands) included in cross-sectional study 252 patients with sarcoidosis (mean age, 53.1 years; 53.2% men), 317 with interstitial lung disease (ILD, mean age, 70 years; 61.5% men), and 48 healthy control subjects (mean age, 36.5 years; 31.3% men). The SpiroNose (Breathomix, Leiden, The Netherlands) was used for exhaled breath analysis. Participants were instructed to perform five tidal breaths, followed by an inhalation to total lung capacity, a 5 second breath hold, and a slow expiration. To explore if breathprints correlate with disease activity, the soluble interleukin-2 receptor (sIL-2R) level was used as a marker for activity. In the laboratory, an sIL-2R value ≤ 550 U/mL was considered normal.

The team reported that eNose distinguished sarcoidosis from control subjects with an area under the curve (AUC) of 1.00 and pulmonary sarcoidosis from other ILD (AUC, 0.87) and hypersensitivity pneumonitis (AUC, 0.88). Exhaled breath of sarcoidosis patients with and without pulmonary involvement, pulmonary fibrosis, multiple organ involvement, pathology-supported diagnosis, and immunosuppressive treatment revealed no distinctive differences. Breath profiles differed between patients with a slightly and highly elevated soluble IL-2 receptor level (median cutoff, 772.0 U/mL; AUC, 0.78).

Iris G. van der Sar, MD, the lead author of the study, said, “Currently, diagnosis of sarcoidosis is challenging due to great differences in clinical presentation often requiring invasive diagnostic procedures such as biopsies. The accuracy of eNose technology is much higher than for other diagnostic tests used in clinical practice for sarcoidosis patients. Building a diagnostic algorithm will allow doctors to use the eNose technology in clinical decision-making in the future.”

The authors concluded that their study showed a reliable and accurate differentiation of patients with sarcoidosis from patients with ILD and healthy control subjects, based on eNose data. The results confirm the potential of eNose technology as a noninvasive diagnostic tool to obtain an early, accurate sarcoidosis diagnosis and reduce the number of invasive diagnostic procedures in the diagnostic trajectory. The study was published on March 1, 2022 in the journal Chest.

Related Links:
Erasmus Medical Center 
Breathomix 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.